Validation of an UV spectrophotometric assay for the quantification of polymyxin B in solid lipid nanoparticles

Autor(es)

Severino, P. ^{[1, 2, 3]} ; Silveira, E. F. ^{[2, 3]} ; Vazzana, M. ^[4] ; Chaud, M. V. ^[5] ; Santana, M. H. A. ^[1] ; Souto, E. B. ^{[6, 7, 8]}

Afiliação do(s) autor(es)

^[1] State Univ Campinas UNICAMP, Sch Chem Engn, Biotechnol Proc Dev Lab, Campinas, SP - Brazil

^[2] Univ Tiradentes Unit, Lab Nanotechnol & Nanomed LNMed, Aracaju - Brazil

^[3] Inst Technol & Res ITP, Aracaju - Brazil

^[4] Univ Messina, Dept Biol & Environm Sci, Messina - Italy

^[5] Univ Sorocaba, Lab Biomat & Nanotechnol Dev & Evaluat Bioact Sub, Sao Paulo - Brazil

^[6] Univ Coimbra, Fac Pharm, Dept Pharmaceut Technol, P-3000548 Coimbra - Portugal

^[7] Univ Coimbra, Ctr Neurosci & Cell Biol, P-3000548 Coimbra - Portugal

^[8] Univ Coimbra, Inst Biomed Imaging & Life Sci CNC IBILI, P-3000548 Coimbra - Portugal

• Tipo de documento: Artigo Científico
• Fonte: Pharmazie; v. 70, n. 11, p. 693-697, NOV 2015.
• Citações Web of Science: 1

Resumo

Polymyxins are efficient antibiotic drugs used for the treatment of Gram-negative bacterial infections. These compounds are not absorbed in the gastrointestinal tract and are responsible for serious toxicological effects. In order to enhance their therapeutic effectiveness, decrease the adverse/toxic side effects and promote a sustained release profile, a derivative-polymyxin B sulphate-has been formulated in solid lipid nanoparticles (SLNs) intended for buccal administration. To quantify polymyxin B in the formulation, UV spectrophotometry analysis was applied, validating the analytical methodology by assessing the selectivity, accuracy, precision, linearity, and repeatability. Analyses were performed at 210nm keeping the samples at 25. degrees C. Results showed that lipid composition of SLNs did not interfere with the polymyxin B spectra. The linearity showed a correlation coefficient of 0.9977 in the range of 5-90 mu g/mL. Quantification of polymyxin B by UV spectrophotometry, at 210nm in SLN formulations, was approved in all analyzed parameters, validating the methodology proposed in this work. (AU)

• Processo FAPESP: 11/20801-2 - Encapsulação dè Polimixina B Èm NLS Pará incorporação Èm hidrogéis mucoadesivos Pará tratamento dè mucosite oral
• Beneficiário: Patricia Severino
• Linha de fomento: Bolsas no Brasil - Pós-Doutorado